| This week in therapeutics |
| Autoimmune disease |
| Autoimmune disease || CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) || In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An in vitro screen identified B7-H2 as a ligand of CD28. In stimulated T cells, a B7-H2-blocking antibody lowered T cell proliferation compared with a control antibody. Next steps include studying the role of B7-H2 in inflammatory tissue. SciBX 4(21); doi:10.1038/scibx.2011.591 Published online May 26, 2011 || Patent application filed; Amplimmune Inc. has an option to license the invention || Yao, S. et al. Immunity; published online April 27, 2011; doi:10.1016/j.immuni.2011.03.014 Contact: Lieping Chen, Yale School of Medicine, New Haven, Conn. e-mail: firstname.lastname@example.org |
| Cancer |
| Breast cancer || CUE domain containing 2 (CUEDC2) || In vitro studies suggest lowering CUEDC2 levels could help increase breast cancer response to hormonal therapy. In human breast cancer cell lines, CUEDC2 overexpression decreased sensitivity to the generic estrogen receptor antagonist tamoxifen compared with that seen using a control plasmid. In human breast tumor samples, CUEDC2 expression was higher than that in adjacent normal tissues and correlated with tamoxifen resistance and poor clinical outcomes. Next steps include validating CUEDC2 as a new biomarker for endocrine therapy and developing a small molecule inhibitor of CUEDC2 to overcome tamoxifen resistance. SciBX 4(21); doi:10.1038/scibx.2011.592 Published online May 26, 2011 || Patent applications filed for diagnostic and therapeutic applications; available for licensing || Pan, X. et al. Nat.
Read the full 2499 word article